drugset / Trial / NCT05379972
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one of therapy.
Timeline
- Start
- 2023-01-12
- Primary completion
- 2025-02-24
- Completion
- 2026-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |